This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cancer Research Technology Limited. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Ngai Yi Mok: Innovator in Cancer Research
Introduction
Ngai Yi Mok is a notable inventor based in Sutton Coldfield, GB. He has made significant contributions to the field of cancer research through his innovative work on quinoline derivatives. His research focuses on developing therapeutic agents aimed at treating and preventing proliferative diseases, particularly cancer.
Latest Patents
Ngai Yi Mok holds a patent for "Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity." This invention relates to compounds of formula I, wherein R, R, and Q are each defined in the patent documentation. The compounds are recognized as inhibitors of the heat shock factor 1 pathway (HSF1 pathway). The patent emphasizes the potential of these compounds as therapeutic agents for the treatment and prevention of various proliferative diseases, including cancer. Additionally, it outlines processes for the preparation of these compounds and pharmaceutical compositions that incorporate them.
Career Highlights
Ngai Yi Mok is associated with Cancer Research Technology Limited, where he continues to advance his research in cancer therapeutics. His work is pivotal in the ongoing battle against cancer, contributing to the development of new treatment options.
Collaborations
He has collaborated with notable colleagues, including Keith Jones and Matthew D Cheeseman, to further enhance the impact of his research in the field of cancer treatment.
Conclusion
Ngai Yi Mok's innovative contributions to cancer research through his patented work on quinoline derivatives highlight his commitment to finding effective treatments for proliferative diseases. His ongoing efforts in collaboration with esteemed colleagues continue to pave the way for advancements in cancer therapeutics.